
To evaluate the safety and efficacy of weekly zzso zzso zzso zzso zzso Company, Princeton, zzso in patients with zzso cancer, participating subjects received standard zzso medication followed by intravenous zzso once a week for 3 weeks every 4 zzso The zzso starting dose was increased by 10 zzso for every five patients, as long as no zzso toxicity had occurred in more than two of five patients treated at the preceding zzso zzso criteria included zzso and zzso zzso zzso an Eastern Cooperative Oncology Group performance status of 0, 1, or 2; and adequate zzso zzso and zzso zzso Of 30 patients treated and zzso for zzso 25 were zzso for zzso The majority of patients tolerated the treatment very zzso In a total of 114 cycles, the worst zzso observed were zzso (one grade 4, two grade zzso zzso (one grade 3, one grade zzso anemia (one grade 3, two grade zzso and infection (one grade 5, one grade zzso Three patients had grade 2 gastrointestinal toxicity and three had grade 1 peripheral zzso Only one zzso zzso at 100 zzso has zzso This patient died of bilateral pneumonia with zzso We have observed partial responses in seven of 12 patients with breast cancer and three of eight with zzso cell lung zzso The study remains open at the current dose level of 100 zzso Weekly zzso zzso is well tolerated and zzso Further phase II studies are warranted, to continue evaluation of this schedule of zzso either alone or in combination with other drugs active in zzso zzso 

